Sugi Predict

Sugi Predict / Compounds / SCHEMBL3095876

SCHEMBL3095876

SCHEMBL3095876

Cn1cc(-c2cnc3ccc(-c4cncc(NS(=O)(=O)c5ccccc5Cl)c4)cc3n2)cn1

nearest known ligand 0.50

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ FGFR3 P22607 8/20 0.50
▸ KDR P35968 8/20 0.50
▸ PRF1 P14222 2/20 0.47
▸ FGFR1 P11362 6/20 0.45
▸ FGFR2 P21802 6/20 0.45
▸ FGFR4 P22455 5/20 0.45
▸ ALPL P05186 2/20 0.44
▸ MAPK1 P28482 1/20 0.42
▸ AURKB Q96GD4 1/20 0.42
▸ PPARG P37231 1/20 0.41
▸ AKT1 P31749 1/20 0.41
▸ PIK3CA P42336 1/20 0.41
▸ SGK1 O00141 1/20 0.41
▸ MET P08581 2/20 0.40
▸ MCL1 Q07820 1/20 0.40
▸ FLT3 P36888 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3074478 0.93 FGFR3 (0.48) FGFR3KDRPRF1FGFR1FGFR2
SCHEMBL3093314 0.91 FGFR3 (0.57) FGFR3KDRALPLSGK1MET
SCHEMBL3096942 0.90 FGFR3 (0.46) FGFR3KDRFGFR1FGFR2FGFR4
SCHEMBL3084748 0.90 PIK3CA (0.53) FGFR3KDRPRF1FGFR1FGFR2
SCHEMBL3092923 0.89 FGFR3 (0.48) FGFR3KDRPRF1FGFR1ALPL
SCHEMBL3080314 0.88 ALPL (0.54) FGFR3KDRPRF1FGFR1FGFR2
SCHEMBL3094941 0.88 PIK3CA (0.50) FGFR3KDRFGFR1FGFR2FGFR4
SCHEMBL3078408 0.87 SLC22A12 (0.50) FGFR3KDRPRF1FGFR1FGFR2
SCHEMBL3088643 0.87 FGFR3 (0.48) FGFR3KDRFGFR1FGFR2FGFR4
SCHEMBL3079491 0.87 ALPL (0.46) FGFR3KDRFGFR1FGFR2FGFR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100234386-A1 QUINOXALINE DERIVATIVES AS PI3 KINASE INHIBITORS SMITHKLINE BEECHAM CORPORATION 2010-09-16 — — US disclosed
US-20100234386-A1 QUINOXALINE DERIVATIVES AS PI3 KINASE INHIBITORS SMITHKLINE BEECHAM CORPORATION 2010-09-16 — — US disclosed
US-20100234386-A1 QUINOXALINE DERIVATIVES AS PI3 KINASE INHIBITORS SMITHKLINE BEECHAM CORPORATION 2010-09-16 — — US disclosed
US-7592342-B2 Quinoxaline derivatives as PI3 kinase inhibitors SMITHKLINE BEECHAM CORPORATION (US) 2009-09-22 — — US disclosed
US-7592342-B2 Quinoxaline derivatives as PI3 kinase inhibitors SMITHKLINE BEECHAM CORPORATION (US) 2009-09-22 — — US disclosed
US-7592342-B2 Quinoxaline derivatives as PI3 kinase inhibitors SMITHKLINE BEECHAM CORPORATION (US) 2009-09-22 — — US disclosed
US-20080293706-A1 QUINOXALINE DERIVATIVES AS PI3 KINASE INHIBITORS GLAXOSMITHKLINE LLC 2008-11-27 — — US disclosed
US-20080293706-A1 QUINOXALINE DERIVATIVES AS PI3 KINASE INHIBITORS GLAXOSMITHKLINE LLC 2008-11-27 — — US disclosed
US-20080293706-A1 QUINOXALINE DERIVATIVES AS PI3 KINASE INHIBITORS GLAXOSMITHKLINE LLC 2008-11-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080293706-A1 QUINOXALINE DERIVATIVES AS PI3 KINASE INHIBITORS PIP5K1A, PIK3CB, PIK3CG FGFR3 2690/4885KDR 1697/4885PRF1 1252/4885
US-20100234386-A1 QUINOXALINE DERIVATIVES AS PI3 KINASE INHIBITORS PIP5K1A, PIK3CB, PIK3CG FGFR3 2690/4885KDR 1697/4885PRF1 1252/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.